Publication | Open Access

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial

Diabetes ManagementSustain 8MedicineDiabetesType 2PharmacotherapyDiabetes MellitusDaily CanagliflozinPharmacology